found Documents: 845

Announcements & Press Releases, Regulatory Notice | 29 Dec 2015

Blocklisting Six Monthly Return

1 item

London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutc

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Dec 2015

Initiation of sulfatinib Phase III registration study in neuroendocrine tumour patients

1 item

London: Friday, 18 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) regist

View Announcement (PDF)

Announcements & Press Releases, Other Ventures, Press Releases | 9 Dec 2015

US$105 million Shanghai land compensation agreement

1 item

Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Dec 2015

Initiation of fruquintinib Phase III registration trial in non-small cell lung cancer

1 item

London: Tuesday, 8 December 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated FALUCA, a Phase III registration study for fruqu

View Announcement (PDF)

Announcements & Press Releases, Group | 13 Nov 2015

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing

1 item

The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM

View Full Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 10 Nov 2015

Results of Extraordinary General Meeting

1 item

London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 9 Nov 2015

Director's Share Dealing

1 item

London: Monday, 9 November 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby makes the following amendments to the "Director's Share Dealing" announcement released on 20 October 2015 subsequent to the notification received from Mr

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 6 Nov 2015

Chi-Med initiates sulfatinib U.S. clinical trials

1 item

London: Friday, 6 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 30 Oct 2015

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

1 item

Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Oct 2015

Total Voting Rights

1 item

London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 30 Oct 2015

Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers

1 item

London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has successfully completed its first-in-human Phase I clini

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 23 Oct 2015

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment

1 item

London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 20 Oct 2015

Director's Share Dealing

1 item

London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has: purchased jointly with his spouse 4,512 ordi

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 19 Oct 2015

Awards under Long Term Incentive Plan

1 item

London: Monday, 19 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that the Remuneration Committee of Chi-Med today granted conditional awards (the “LTIP Awards”) under the Long Term Incentive Plan (the “LTIP

View Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 16 Oct 2015

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing

1 item

Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti

View Announcement (PDF)

Announcements & Press Releases, Group | 16 Oct 2015

Shareholders' Circular and Notice of Extraordinary General Meeting

1 item

London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U

View Announcement (PDF)

Announcements & Press Releases, Group | 16 Oct 2015

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

1 item

The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Oct 2015

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma

1 item

Press Release London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha

View PDF

Announcements & Press Releases, Regulatory Notice | 12 Oct 2015

Holding(s) in Company

1 item

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or t

Download PDF

Announcements & Press Releases, Group | 8 Oct 2015

Winner of International Company of the Year 2015, AIM

At the 2015 AIM Awards, Chi-Med was awarded the title of International Company of the Year. The AIM Awards look at how companies and individuals harness AIM to power their growth and fulfil their strategy. The AIM Awards scrutinises recent joiners

Announcements & Press Releases, Oncology / Immunology | 14 Sep 2015

Fruquintinib Phase II clinical results in colorectal cancer to be presented at the 2015 European Cancer Congress

1 item

London: Monday, 14 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present the detailed clinical results of its Phase II proo

View PDF

Announcements & Press Releases, Oncology / Immunology | 2 Sep 2015

Second proof-of-concept trial of fruquintinib achieves its primary endpoint

1 item

London: Wednesday, 2 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proo

View PDF

Announcements & Press Releases, Oncology / Immunology | 19 Aug 2015

Termination of Research & Development Alliance Agreement with Janssen Relating to HMPL-507 Project

1 item

London: Wednesday, 19 August 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that, Hutchison MediPharma Limited (“HMP”), its R&D subsidiary, has received notice from Janssen Pharmaceutical, Inc. (Janssen) of

View PDF

Announcements & Press Releases, Group | 28 Jul 2015

Interim Results for the Six Months Ended 30 June 2015

1 item

For the complete release, please download the PDF. --- Drug R&D Division - our Innovation Platform: enrolling 17 clinical trials (H1 2014: 10), with 24 targeted by year-end. China Healthcare and Consumer Products Divisions - our Commercial

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 23 Jul 2015

TR-1: Notification of major interest in shares

1 item

View PDF

Announcements & Press Releases, Regulatory Notice | 23 Jul 2015

TR-1: Notification of major interest in shares

1 item

PDF

Announcements & Press Releases, Oncology / Immunology | 23 Jul 2015

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med

1 item

London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui

PDF

Announcements & Press Releases, Other Ventures | 17 Jul 2015

20-year invention patent granted on Chi-Med's best selling prescription drug

1 item

London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven

a150717

Announcements & Press Releases, Regulatory Notice | 6 Jul 2015

Notice of Announcement of 2015 Interim Results

1 item

London: Monday, 6 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) will be announcing its interim results for the six months ended 30 June 2015 on Tuesday, 28 July 2015. An analyst presentation will be held at 9:00 am on the same d

a150706

Announcements & Press Releases, Regulatory Notice | 29 Jun 2015

Blocklisting Six Monthly Return

1 item

London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM)announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of

a150629

Announcements & Press Releases, Oncology / Immunology | 1 Jun 2015

Savolitinib (AZD6094) preliminary Phase Ib clinical data in lung cancer presented at the 2015 ASCO Annual Meeting

1 item

London: Monday, 1 June 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM), today announces that AstraZeneca AB (publ) (“AstraZeneca”), Hutchison MediPharma Limited’s (“HMP”) collaboration partner, presented preliminary data f

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 May 2015

Positive fruquintinib proof-of-concept study results trigger payments from Lilly

1 item

London: Wednesday, 13 May 2015: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned drug R&D company, is set to receive a total of US$18 million in payments, in the second quarter of 2015, from Eli Lilly and

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Apr 2015

Total Voting Rights

1 item

London: Thursday, 30 April 2015: For information purposes, Chi-Med hereby notifies the market that as at 30 April 2015, the issued share capital of Chi-Med consisted of 53,299,964 ordinary shares of US$1.00 each, with each share carrying one right to

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 24 Apr 2015

Results of Annual General Meeting

1 item

London: Friday, 24 April 2015: Chi-Med today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on 24 April 2015 were duly passed. Please download the PDF.

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 22 Apr 2015

Director's Shareholding

1 item

London: Wednesday, 22 April 2015: Chi-Med received notification on 22 April 2015 that Mr Christopher Nash, Independent Non-executive Director, has purchased 1,388 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP18.00 pe

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 16 Apr 2015

Director's Shareholding

1 item

London: Thursday, 16 April 2015: Chi-Med received notification on 16 April 2015 that Simon To, Executive Director and Chairman, has purchased 28,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP15.85 per share on 15

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 13 Apr 2015

Director's Shareholding

1 item

London: Monday, 13 April 2015: Chi-Med received notification on 13 April 2015 that Simon To, Executive Director and Chairman, has purchased 25,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP14.215 per share on 10 A

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 8 Apr 2015

Directors' Shareholding

1 item

London: Wednesday, 8 April 2015: Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 1 Apr 2015

Directors' Shareholding

1 item

London: Wednesday, 1 April 2015: Chi-Med received notifications on 1 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase Numbe

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 1 Apr 2015

Exercise of Options

1 item

London: Wednesday, 1 April 2015: Chi-Med announces that it has issued 64,038 ordinary shares of US$1.00 each (the "Shares") following the exercise of options by Mr Johnny Cheng, Executive Director and Chief Financial Officer of Chi-Med, at an exercis

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 30 Mar 2015

The first proof-of-concept trial of fruquintinib achieves primary efficacy endpoint

1 item

London: Monday, 30 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, successfully achieved the primary endpoint in the first proof-of-concept ("POC") trial of fruquintinib in pati

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 23 Mar 2015

2014 Annual Report and Notice of Annual General Meeting

1 item

London: Monday, 23 March 2015: Chi-Med today announces that its 2014 Annual Report together with the Notice of Annual General Meeting and the Proxy Form have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 18 Mar 2015

TR-1: Notification of major interest in shares

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 6 Mar 2015

Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer; Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer

1 item

London: Friday, 6 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung

View Announcement (PDF)

Announcements & Press Releases, Group | 26 Feb 2015

Final Results for the year ended 31 December 2014

1 item

For the complete release, please download the PDF. -- Break-out year for Drug R&D Division with 16 clinical studies on 7 drug candidates; 10 potential Breakthrough Therapy indications; as well as record China Healthcare Division revenues and

View Announcement (PDF)

Announcements & Press Releases, Other Ventures, Press Releases | 29 Jan 2015

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China

1 item

Press Release - London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"),

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 26 Jan 2015

Notice of Announcement of 2014 Final Results

1 item

London: Monday, 26 January 2015: Chi-Med will be announcing its final results for the year ended 31 December 2014 on Thursday, 26 February 2015. An analyst presentation will be held at 9:00 am on the same day at Citigate Dewe Rogerson, 3 London Wall

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Dec 2014

Total Voting Rights

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Dec 2014

Blocklisting Six Monthly Return

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 15 Dec 2014

Initiation of fruquintinib Phase III registration study in colorectal cancer

1 item

London: Monday, 15 December 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated FRESCO, a Phase III registration study in colorectal cancer (“CRC”) patients in China, for

View Announcement (PDF)

1 2 3 4 5 6 7 8 9 10 11 12

14 15 16 17